Presenting the Evidence for Patent Eligibility Reform: Part II – Harm to R&D Investment, Innovation and U.S. Interests
Amgen Says Solicitor General’s ‘Disagreement With Everyone’ Further Supports SCOTUS Review of Legal Standard for Enablement
SCOTUS Week in Review: Cert Denied in Cases Challenging Fairness of IPR Institutions, Application of Alice/Mayo; SG Briefing Requested in Teva’s ‘Skinny Label’ Case